Cargando…
Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
OBJECTIVE: The objective of this study is to evaluate the expression of different nicotinic acetylcholine receptors (nAChRs), programmed death ligand-1 (PD-L1), and dopamine receptor D2 (DRD2) as prognostic factors in lung cancer and any correlation among them. Since all of the above genes are typic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441878/ https://www.ncbi.nlm.nih.gov/pubmed/36072788 http://dx.doi.org/10.3389/fonc.2022.959500 |
_version_ | 1784782685891198976 |
---|---|
author | Pal, Krishnendu Hussain, Tabish Xie, Hao Li, Shenduo Yang, Ping Mansfield, Aaron Lou, Yanyan Chowdhury, Shantanu Mukhopadhyay, Debabrata |
author_facet | Pal, Krishnendu Hussain, Tabish Xie, Hao Li, Shenduo Yang, Ping Mansfield, Aaron Lou, Yanyan Chowdhury, Shantanu Mukhopadhyay, Debabrata |
author_sort | Pal, Krishnendu |
collection | PubMed |
description | OBJECTIVE: The objective of this study is to evaluate the expression of different nicotinic acetylcholine receptors (nAChRs), programmed death ligand-1 (PD-L1), and dopamine receptor D2 (DRD2) as prognostic factors in lung cancer and any correlation among them. Since all of the above genes are typically upregulated in response to smoking, we hypothesized that a correlation might exist between DRD2, PD-L1, and nAChR expression in NSCLC patients with a smoking history and a prediction model may be developed to assess the clinical outcome. METHODS: We retrospectively analyzed samples from 46 patients with primary lung adenocarcinoma who underwent surgical resection at Mayo Clinic Rochester from June 2000 to October 2008. The expression of PD-L1, DRD2, CHRNA5, CHRNA7, and CHRNA9 were analyzed by quantitative PCR and correlated amongst themselves and with age, stage and grade, smoking status, overall survival (OS), and relapse-free survival (RFS). RESULTS: Only PD-L1 showed a statistically significant increase in expression in patients older than 65. All the above genes showed higher expression in stage IIIB than IIIA, but none reached statistical significance. Interestingly, we did not observe significant differences among never, former, and current smokers, but patients with pack years greater than 30 showed significantly higher expression of CHRNA9. We observed a strong positive correlation between PD-L1/DRD2, PD-L1/CHRNA5, and CHRNA5/CHRNA7 and a weak positive correlation between DRD2/CHRNA5 and DRD2/CHRNA7. Older age was independently associated with poor OS, whereas lower CHRNA7 expression was independently associated with better OS. CONCLUSIONS: We observed strong positive correlations among PD-L1, DRD2, and some of the nAChRs. We investigated their prognostic significance in lung cancer patients and found CHRNA7 to be an independent prognostic factor. Overall, the results obtained from this preliminary study warrant a large cohort-based analysis that may ultimately lead to potential patient-specific stratification biomarkers predicting cancer-treatment outcomes. |
format | Online Article Text |
id | pubmed-9441878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94418782022-09-06 Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma Pal, Krishnendu Hussain, Tabish Xie, Hao Li, Shenduo Yang, Ping Mansfield, Aaron Lou, Yanyan Chowdhury, Shantanu Mukhopadhyay, Debabrata Front Oncol Oncology OBJECTIVE: The objective of this study is to evaluate the expression of different nicotinic acetylcholine receptors (nAChRs), programmed death ligand-1 (PD-L1), and dopamine receptor D2 (DRD2) as prognostic factors in lung cancer and any correlation among them. Since all of the above genes are typically upregulated in response to smoking, we hypothesized that a correlation might exist between DRD2, PD-L1, and nAChR expression in NSCLC patients with a smoking history and a prediction model may be developed to assess the clinical outcome. METHODS: We retrospectively analyzed samples from 46 patients with primary lung adenocarcinoma who underwent surgical resection at Mayo Clinic Rochester from June 2000 to October 2008. The expression of PD-L1, DRD2, CHRNA5, CHRNA7, and CHRNA9 were analyzed by quantitative PCR and correlated amongst themselves and with age, stage and grade, smoking status, overall survival (OS), and relapse-free survival (RFS). RESULTS: Only PD-L1 showed a statistically significant increase in expression in patients older than 65. All the above genes showed higher expression in stage IIIB than IIIA, but none reached statistical significance. Interestingly, we did not observe significant differences among never, former, and current smokers, but patients with pack years greater than 30 showed significantly higher expression of CHRNA9. We observed a strong positive correlation between PD-L1/DRD2, PD-L1/CHRNA5, and CHRNA5/CHRNA7 and a weak positive correlation between DRD2/CHRNA5 and DRD2/CHRNA7. Older age was independently associated with poor OS, whereas lower CHRNA7 expression was independently associated with better OS. CONCLUSIONS: We observed strong positive correlations among PD-L1, DRD2, and some of the nAChRs. We investigated their prognostic significance in lung cancer patients and found CHRNA7 to be an independent prognostic factor. Overall, the results obtained from this preliminary study warrant a large cohort-based analysis that may ultimately lead to potential patient-specific stratification biomarkers predicting cancer-treatment outcomes. Frontiers Media S.A. 2022-08-22 /pmc/articles/PMC9441878/ /pubmed/36072788 http://dx.doi.org/10.3389/fonc.2022.959500 Text en Copyright © 2022 Pal, Hussain, Xie, Li, Yang, Mansfield, Lou, Chowdhury and Mukhopadhyay https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Pal, Krishnendu Hussain, Tabish Xie, Hao Li, Shenduo Yang, Ping Mansfield, Aaron Lou, Yanyan Chowdhury, Shantanu Mukhopadhyay, Debabrata Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma |
title | Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma |
title_full | Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma |
title_fullStr | Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma |
title_full_unstemmed | Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma |
title_short | Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma |
title_sort | expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor d2 in lung adenocarcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441878/ https://www.ncbi.nlm.nih.gov/pubmed/36072788 http://dx.doi.org/10.3389/fonc.2022.959500 |
work_keys_str_mv | AT palkrishnendu expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT hussaintabish expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT xiehao expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT lishenduo expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT yangping expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT mansfieldaaron expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT louyanyan expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT chowdhuryshantanu expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma AT mukhopadhyaydebabrata expressioncorrelationandprognosticsignificanceofdifferentnicotinicacetylcholinereceptorsprogrameddeathligand1anddopaminereceptord2inlungadenocarcinoma |